Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Laura Sabatino
 -- 3442 2023-06-13 17:29:38 |
2 Reference format revised.
Lindsay Dong
 Meta information modification 3442 2023-06-15 03:30:31 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Della Nera, G.; Sabatino, L.; Gaggini, M.; Gorini, F.; Vassalle, C. Vitamin D in Cardiovascular Risk and Disease. Encyclopedia. Available online: https://encyclopedia.pub/entry/45521 (accessed on 19 May 2024).
Della Nera G, Sabatino L, Gaggini M, Gorini F, Vassalle C. Vitamin D in Cardiovascular Risk and Disease. Encyclopedia. Available at: https://encyclopedia.pub/entry/45521. Accessed May 19, 2024.
Della Nera, Giulia, Laura Sabatino, Melania Gaggini, Francesca Gorini, Cristina Vassalle. "Vitamin D in Cardiovascular Risk and Disease" Encyclopedia, https://encyclopedia.pub/entry/45521 (accessed May 19, 2024).
Della Nera, G., Sabatino, L., Gaggini, M., Gorini, F., & Vassalle, C. (2023, June 13). Vitamin D in Cardiovascular Risk and Disease. In Encyclopedia. https://encyclopedia.pub/entry/45521
Della Nera, Giulia, et al. "Vitamin D in Cardiovascular Risk and Disease." Encyclopedia. Web. 13 June, 2023.
Vitamin D in Cardiovascular Risk and Disease
Edit
This entry is adapted from the peer-reviewed paper 10.3390/antiox12040948

Beyond its key role in calcium homeostasis, vitamin D has been found to significantly affect the cardiovascular (CV) system. In fact, low vitamin D levels have been associated with increased CV risk, as well as increased CV morbidity and mortality. The majority of effects of this molecule are related directly or indirectly to its antioxidative and anti-inflammatory properties. Generally, vitamin D insufficiency is considered for 25-hydroxyvitamin D (25(OH)D) levels between 21–29 ng/mL (corresponding to 52.5–72.5 nmol/L), deficiency as 25(OH)D levels less than 20 ng/mL (<50 nmol/L), and extreme deficiency as 25(OH)D less than 10 ng/mL (<25 nmol/L). However, the definition of an optimal vitamin D status, as defined by 25(OH)D, remains controversial for many extra-bone conditions, including CV disease. 

vitamin D 25(OH)D antioxidant determinants vitamin D status cardiovascular risk cardiovascular disease

1. Introduction

It is well known that the role of vitamin D extends well beyond the traditional effect on muscle and bone health, now including a number of extra-bone conditions, such as cancer, diabetes, and cardiovascular disease (CVD), many of them related to the antioxidant and anti-inflammatory in which this molecule is involved [1]. Thus, an increase in requests for serum total 25(OH)D, widely recognized as the most reliable marker of vitamin D status, has exponentially grown in the last few years as a consequence of its clinical value, in parallel to the improvement of methodological and standardization-related aspects. However, reference values of vitamin D are still not clearly defined. The Endocrine Society advised reaching serum 25(OH)D levels of at least 30 ng/mL (>75 nmol/L), preferentially to maintain levels in the range of 40–60 ng/mL (100–150 nmol/L) [2]. Accordingly, vitamin D insufficiency is generally considered for 25(OH)D levels between 21–29 ng/mL (corresponding to 52.5–72.5 nmol/L), deficiency as 25(OH)D levels less than 20 ng/mL (<50 nmol/L), and extreme deficiency as 25(OH)D less than 10 ng/mL (<25 nmol/L) [2]. Nonetheless, the Institute of Medicine (IOM) recommended 20 ng/mL as the threshold for physiologically adequate levels of 25(OH)D [3]. In any case, according to these categories, a large percentage of the entire world population can show inadequate serum 25(OH)D levels, especially when considering obese subjects, people with dark skin, and those insufficiently exposed to sunlight, making it necessary to assess the significance of these findings in terms of disease risk [4]. In addition, it has been estimated that a considerable number of children and adolescents are at high risk for vitamin D deficiency and insufficiency worldwide [5].

2. Vitamin D Metabolism

UVB sun rays are the main source of vitamin D, whereas less than 10% derives from dietary intake (e.g., salmon, mackerel and herring, mushrooms, eggs, and fish liver oil), but may be also added to other foods or available as a dietary supplement. Skin exposure to solar UV irradiation induces photolysis of a derivative of cholesterol (7-dehydrocholesterol) into pre-vitamin D3, then isomerized to vitamin D3 (cholecalciferol) [1]. As a liposoluble/hydrophobic molecule, vitamin D3 requires the binding with a transporter protein (vitamin D-binding protein, VDBP) to circulate in the blood. Then, it is hydroxylated in the liver to form 25(OH)D, the major circulating metabolite [1]. In the kidney, hydroxylation catalyzed by the 1alfa-hydroxylase enzyme produces the active hormone, 1,25-dihydroxy vitamin D (1,25(OH)2D), while 24-hydroxylase (CYP24) promotes the production of inactive forms [1]. When released by its binding with DBP to the tissues, 1,25(OH)2D mediates a number of actions through its intracellular vitamin D receptor (VDR). The main objectives are control of calcium and phosphorus homeostasis (kidney and intestine as principal target tissues) and bone health and turnover. Although 1,25(OH)2D represents the active form, there is general agreement on the measure of 25(OH)D as the best index of vitamin D status [2]. Notably, 25(OH)D has a higher concentration in the bloodstream with respect to the active form 1,25(OH)2D and shows a longer circulating half-life if compared to 1,25(OH)2D (3 weeks vs. 4 h, respectively), thus providing more representative information about the vitamin D status. Moreover, 1,25(OH)2D values are regulated through PTH (upregulation) and higher serum calcium and phosphate levels (downregulation). Therefore, because vitamin D deficiency may induce secondary hyperparathyroidism, 1,25(OH)2D may result in reduced, normal or even elevated despite evidence of vitamin deficiency.

3. Methodological Determinants

3.1. Preanalytical Issues

25(OH)D is generally measured in plasma or serum samples, although serum is the most used. In some cases, 25(OH)D levels were found to be higher in heparinized plasma than in serum samples or in ethylenediamine tetraacetic acid (EDTA) plasma [6][7][8]. When tubes with gel are used, no impediment for immunoassay evaluation was registered, whereas interferences have been observed with high-performance liquid chromatography (HPLC) or mass spectrometry approaches [6][9].
Different storage conditions (fresh samples vs. up to 24 h at room temperature, different centrifuging times/temperature, multiple freeze–thaw cycles) did not significantly affect 25(OH)D values [6][8][9][10][11][12]. Long-term stability of 25(OH)D at −20 °C and −80 °C is generally acceptable, although a 15% variation after two months [13] or significant loss after four months at −20 °C was observed [6]. In addition, a variation of 25(OH)D levels after five years of storage also at low temperature (−80 °C) has been reported, which may be taken into consideration for studies involving sample long-term storage [14].

3.2. Analytical Issues

There are several different analytical assays available for the determination of 25(OH)D, which include immunoassays (e.g., chemiluminescence immunoassay-CLIA and radioimmunoassay-RIA, high-performance liquid chromatography-HPLC with UV/fluorescence detection, liquid chromatography-mass spectrometry-LC-MS or tandem mass spectrometry-LC-MS/MS) [15][16]. Although LC-MS/MS maintains high analytical performance, aspects related to the high cost of instruments, time-consuming, limited throughput, and complexity of methodological problems requiring skilled professional staff, greatly limit the inclusion of this technique in clinical practice. Thus, the introduction of automated immunoassays has enabled rapid uptake of testing and the ability to respond to an ever-increasing demand for vitamin D testing (with the exception of RIA, due to available alternatives that avoid radiolabeled compounds). Nonetheless, these assays still present a highly variable analytical performance, and many cross-reactivity problems with several vitamin D metabolites as well as matrix effects (e.g., heterophilic antibodies) [14].

4. Environmental Determinants, Lifestyle Habits, and Skin Pigmentation Affecting 25(OH)D Status

A variety of biological and environmental factors can influence vitamin D status in humans [17]. (Table 1). Synthesis of vitamin D in human skin occurs under ultraviolet exposure, thus any factor (e.g., season, latitude, time of day, cloud, ozone) influencing ultraviolet radiation levels, may significantly affect vitamin D production [18][19]. The day length, which is the period between sunrise and sunset, is dependent on latitude and time of the year, thereby peak levels of 25(OH)D are recorded following the summer months [20][21].
Table 1. Environmental, anthropometric, and lifestyle determinants affecting 25(OH)D levels.
Environmental Determinants Anthropometric Determinants Life-Style Determinants

sunlight exposure: intensity and duration
season
latitude
length of day
presence of clouds
air pollution/ozone		 aging
race/phototype
gender
body mass index/obesity
genetic asset: presence of specific polymorphisms
hepatic/renal dysfunction
pregnancy
dietary intake

supplementation/fortified foods

sunscreen/clothes

time spent outdoor/outdoor sports
Thus, due to seasonal changes based on sunlight exposure, it would be preferable to evaluate the annual variation to adequately estimate the vitamin D status in each subject [6][22][23][24][25]. Indeed, approximately 85% of the world population lives at latitudes between the 40th parallel north and south and, consequently, these individuals are routinely exposed to sunlight [26]. The remainder population (15%) lives at higher latitudes, receiving relatively lower amounts of sunshine, and in late winter/early spring their vitamin D status typically declines and reaches its nadir [27][28][29].

5. Anthropometric Characteristics

Differences in age together with other factors, including vitamin D receptor gene polymorphisms, and constitutive skin pigmentation are responsible for a not negligible part (up to 15%) of the interpersonal variation in the UVB-induced 25(OH)D synthesis in the skin [30]. It is known that the ability to produce vitamin D3 is impaired in the elderly, with an aging-related progressive reduction in skin levels of 7-dehydrocholesterol [31]. This effect can be further exacerbated by reduced nutritional intake of vitamin D, increasing adiposity, less exposure to sunlight due to immobility, and staying indoors, all common factors in adult aging [31][32]. Additionally, as the kidney plays a central role in the regulation of vitamin D metabolism and circulating levels, a reduced renal function can lead to the inhibition of renal 1α-hydroxylase expression, upregulation of 24-hydroxylase and 1,25(OH2)D degradation, and the resulting vitamin D deficiency observed among patients with chronic kidney disease or undergoing dialysis [33][34]. Vitamin D status could also vary according to sex, although there is contrasting evidence as regards this association [35]. In this context, Muscogiuri et al. (2019) found that 25(OH)D levels were lower in females than males across all body mass index (BMI) categories [35].
25(OH)D is lipophilic and it has been estimated that about 17% of orally-administered vitamin D dose is stored in adipose tissue and the rest is consumed or metabolized, indicating that adipose tissue acts both as a storage and buffering site of vitamin D [36][37]. Accordingly, clinical studies have found that obese individuals have a greater risk (35–40%) of vitamin D deficiency, regardless of age and latitude [38][39][40]. Vitamin D has been shown to affect adipocyte development, although results from in vitro and in vivo studies assessing the effect of vitamin D in adipogenesis are conflicting [37][41]. 

6. Vitamin D and Genetic Determinants

Besides environmental and nutritional aspects, circulating levels of vitamin D are also influenced by genetic patterns. Many investigations on the causal role between vitamin D and several diseased conditions relied on studies on identical and non-identical twin pairs, which normally have similar trait-relevant environments [42] and allow better esteem taking into account genetics and/or environmental effects. These studies have shown that vitamin D concentrations are highly heritable, between 29% and 86% [42][43][44]. In general, the considerable variance in the evaluation of vitamin D heritability depends on many different reasons, such as age, gender, seasonality, and comorbidities [45]. Therefore, well-powered twin studies with reliable controls are fundamental in the determination of genetic contribution to the vitamin D circulating component.
Over time, the studies of genetic determinants associated with the modification of vitamin D circulating levels in humans proceeded through several stages. The first classical approach was the linkage analysis of specific genetic intervals on the chromosome and their relation to the disease [46][47]. In general, linkage analysis conducted on affected subjects of the same family unveils which locus segregates with certain disease/phenotype; therefore, this approach may help to identify which chromosome region(s) may be associated with vitamin D variability in many diseases [46].
Differently from the linkage analysis-based studies, the candidate gene approach and genome-wide association study (GWAS) allowed the identification of reliable and reproducible associations with vitamin D circulating concentration. By candidate gene studies, it is possible to define if the frequency of a specific variant (single nucleotide polymorphism or gene) is associated with the variation of vitamin D levels, usually in the context of unrelated subjects. Several genes, closely related to vitamin D metabolism, have been studied: CYP2R1 and CYP27B1, involved in vitamin D hydroxylation [48]; GC, encoding for a vitamin D carrier protein [49]; VDR, coding for Vitamin D receptor [49]; CYP24A1, a cytochrome P450 gene [50]. 
GWAS constituted the major advancement in the identification of novel links between specific diseases and their biological determinants. Instead of focusing on a limited number of specific gene variations as in candidate gene studies, this innovative approach, which relies on the haplotype map of the genome and array-based advanced technology, rapidly explores the whole genome. The first GWAS of vitamin D consisted of 1012 related subjects from the Framingham Heart Study and genotyped 70,987 SNPs. However, because of the limited power and coverage of the analysis, none of the SNPs has passed the genome-wide significant p threshold at 5 × 10−8, obtained from Bonferroni’s correction for multiple testing [51]. Ultimately, important key findings on vitamin D genetics were obtained though large-scale international efforts to perform GWAS meta-analyses, involving large numbers of individuals from different cohorts, so as to obtain sufficient statistical power to reliably identify an association between circulating vitamin D levels and genetic determinants of several health outcomes [52].

7. Vitamin D Mechanisms Related to Its Antioxidant/Antiinflammatory Action and Vascular Health

If a causal role of vitamin D for bone health is widely recognized, with vitamin D deficiency associated with most cases of rickets and osteomalacia, a number of genetic, molecular, cellular, and animal studies strongly suggest that vitamin D signaling has many extraskeletal effects, including regulation of cell proliferation, immune and muscle function, skin differentiation, and reproduction, as well as vascular and metabolic properties, which are not strictly related to calcium homeostasis [53][54]. On the other hand, these extraskeletal effects are characterized by some controversies due to conflicting results between observational and interventional studies [55]. Nonetheless, it is well established that vitamin D is able to modulate immune response (Th1/Th2 reduction) [56], while vitamin D deficiency has been associated with numerous conditions (e.g., multiple sclerosis, type 1 diabetes, rheumatoid arthritis, systemic lupus erythematosus, hepatitis, asthma, respiratory infections) and with an increased risk of any type of cancer and a reduced survival rate [55][57].
The biological effects of vitamin D are mediated by VDR, a member of the transcription factor superfamily of nuclear receptors which, upon activation by its binding to the active form of vitamin D and to a retinoid X receptor, translocate to the nucleus where it may regulate the transcription of vitamin D-sensitive target genes within hours or days [58].
Nitric oxide (NO), produced in the endothelium by endothelial NO synthase (eNOS), in addition to its potent vasodilatory effect, protects the vessels from developing atherosclerosis [59]. Experimental studies reported the ability of vitamin D to stimulate NO production via a direct increase of eNOS gene expression and activation of eNOS in intracellular calcium-dependent pathways (Figure 1) [60][61]. Vitamin D elicits a vasoprotective effect also through a decrease of oxidative stress (a major indicator of NO bioavailability and cause of damage to protein, lipids, and DNA), by upregulating expression of antioxidative enzymes and activating the nuclear factor erythroid 2-related factor 2 antioxidant pathway (Figure 1) [62][63][64].
/media/item_content/202306/648a68bb753caantioxidants-12-00948-g001.png
Figure 1. Main Vitamin D mechanisms of actions related to oxidative stress and inflammatory processes and vascular health. ↑ increase, ↓ decrease.
The chronic inflammation process, which is mediated by several factors, including cell-derived proinflammatory cytokines such as tumor necrosis factor-alpha (TNFα) and interleukin (IL)-1 and IL-6, contributes to the development of endothelial dysfunction, atherosclerosis, and CVD (Figure 1) [59]. The active metabolite of vitamin D has an anti-inflammatory effect through negative regulation of nuclear factor κB (NF-κB) and STAT1/5-mediated signaling, which leads to the downregulation of expression and production of several pro-inflammatory cytokines (TNF-α, IL-1, IL-2β, monocyte chemoattractant protein-1) [65]. 
Renin–angiotensin–aldosterone system (RAAS), a regulatory cascade having a crucial impact on the cardiovascular system tonus through the production of angiotensin II, increases vasoconstriction, extracellular volume, and cardiac output, and represents a major target of vitamin D (Figure 1) [66][67]. In mice, vitamin D was shown to suppress renin transcription by a VDR-mediated mechanism independent of extracellular calcium or phosphorus, which could block the cyclic AMP signaling pathway, a signaling pathway that plays a critical role in renin transcription and release in response to various physiological factors [68][69][70]. The fundamental role of vitamin D in regulating RAAS has been reported in animal models [69][70][71] but, with inconsistent results, in humans [72][73][74]. In fact, although most of the observational studies reported an inverse association between vitamin D and the incidence of hypertension [75][76], pooled results of randomized controlled trials (RCTs) showed that there was no significant reduction in systolic blood pressure or diastolic blood pressure following vitamin D supplementation in the general population [76][77] but may slightly decrease peripheral blood pressure in vitamin D-deficient patients [78]. Notably, the role of vitamin D deficiency in arterial hypertension could be also explained by decreased bioavailability of NO and atherosclerosis, and not exclusively by RAAS hyperactivation [58][61][79]. As for arterial stiffness, a strong predictor of CV events and all-cause mortality, in the meta-analysis of 18 RCTs by Rodriguez et al. (2016), no evidence of significant associations was found between vitamin D supplementation and reductions in pulse wave velocity (PWV) (Figure 1) [80]. 

8. Observational Studies

An inverse relationship between circulating vitamin D levels and different biomarkers related to oxidative stress and inflammation has been found in subjects with cardiometabolic risk or patients with CV disease. In particular, obese subjects (children and adolescents or adults) or T2D patients with hypovitaminosis D presented elevated levels of oxidative stress and inflammatory biomarkers, and an inverse correlation is also found between 25(OH)D and levels of different oxidative stress and inflammatory biomarkers [81][82][83][84][85][86]. In coronary artery disease (CAD) patients, an inverse relationship between vitamin D and homocystine (Hcy) was observed. Moreover, the association of Hcy with CAD severity was significant only among patients with hypovitaminosis D, suggesting that an adequate vitamin D status can prevent the adverse consequences of hyperhomocysteinemia on coronary atherosclerosis [87]. Always in CAD patients, an inverse association between gamma-glutamyltransferase (GGT, another oxidative-related biomarker) and 25(OH)D levels was found [88]. In acute myocardial infarction (AMI), vitamin D was inversely related to metalloproteinases (MMP-2) and leptin, biomarkers known as involved in CAD and AMI [89]. Accordingly, overall, most observational studies have reported an inverse association between vitamin D levels and CVD [54].
In order to assess the relevance of plasma concentrations of 25(OH)D for vascular mortality, a meta-analysis including 12 prospective studies (published up to January 2012) with 4632 vascular deaths, showed that subjects with 25(OH)D in the highest vs. the lowest quarter of distribution, had on average, 21% (95% CI: 13–28%) lower vascular mortality [90]. These results were supported by a following meta-analysis that used data from eight independent prospective cohort studies from Norway, Germany, Iceland, Denmark, and the Netherlands, for a total of 26,916 participants. After adjustment for age, sex, season of blood drawing, BMI, active smoker status, history of CVD, the authors reported that, compared to subjects with 25(OH)D concentrations of 75 to 99.99 nmol/L, the adjusted hazard ratios (HRs) for CV mortality in the 25(OH)D groups with 40 to 49.99, 30 to 39.99, and <30 nmol/L, were 1.65 (95% CI 1.39–1.97), 1.61 (95% CI 1.46–1.77), and 2.21 (1.50–3.26), respectively [91]. 
These findings are consistent with the increased likelihood of CVD risk factors in older adults, however, the heterogeneity of measurement assays of vitamin D across studies may represent a non-negligible confounding factor [92]. Conversely, within a previous dose-response meta-analysis of 34 prospective studies for a total of 180,667 participants, Zhang and co-workers found that for 10 ng/mL increment of serum 25(OH)D, pooled RRs were 0.90 (95% CI: 0.86–0.94) and 0.88 (95% CI: 0.80–0.96) for total CVD events and CVD mortality, respectively, although it should be evidenced that the number of participants with high concentrations of serum 25(OH)D was small [93].

9. Randomized Controlled Trials

Despite extensive evidence suggesting a consistent link between vitamin D and CVD coming from observational studies, overall systematic reviews, and meta-analyses of RCTs did not support any indisputable clear beneficial effect of vitamin D supplementation on CV mortality and risk of total CV events, stroke, and myocardial infarction or ischaemic heart disease, suggesting that vitamin D supplementation does not confer indisputable CV protection. Indeed, Elamin et al. (2012), after having selected 51 eligible studies for a meta-analysis, found no significant impact of vitamin D on MI or stroke and, similarly, on the main CV risk factors (blood lipids, blood glucose, and blood pressure measurements) [94].
For it concerns the effect of vitamin D supplementation on biomarkers of oxidative stress/inflammation in healthy subjects, it is noteworthy that different biomarker profiles (e.g., total antioxidant capacity-TAC, glutathione, C reactive protein) improve, although for other parameters there is not a clear significant benefit (e.g., malondialdehyde-MDA and carbonyl groups) [95][96][97][98][99]. However, daily intake of vitamin D (150 mg of calcium + 500 IU vitamin D per 250 mL/12 weeks) significantly decreased serum protein carbonyl levels in healthy adults [100]. In T2D hemodialysis patients, vitamin D supplementation induces a significant reduction in hsC-reactive protein and MDA, in parallel to a significant increase in TAC levels [101]. Some data suggested that vitamin D may reduce or prevent the disease progression and cardiovascular risk in T2D patients by decreasing oxidative stress and platelet-mediated inflammation (IL-18, TNF-α, IFN-γ, CXCL-10, CXCL-12, CCL-2, CCL-5, CCL-11, and PF-4), as well as blood vitamin D supplementation (2000 IU/day for six months) in T2D patients having vitamin D < 20 ng/mL resulted associated to a significant decrease in OxLDL, hsCRP, IL-6, PAI-1, and fibrinogen levels and a significant increase in FRAP, (although other studies failed to evidence any significant effect on different biomarkers of oxidative stress and inflammation in these type of patients) [102][103][104][105]. 
In summary, results from interventional studies, in general, do not support the routine use of vitamin D supplementation, although this strategy could be useful in certain subgroups, where its use may improve metabolic parameters, reducing oxidative stress, inflammation, and CV outcomes [106]. However, it should be noted that the small sample size, the relatively short duration of vitamin D supplementation, and heterogeneity in terms of vitamin D dose, duration of treatment, comorbid conditions, population characteristics, choice of oxidative or inflammatory biomarkers, and assessment of baseline 25(OH)D level across trials could affect the reported results [107].

References

  1. Silva, I.C.J.; Lazaretti-Castro, M. Vitamin D Metabolism and Extraskeletal Outcomes: An Update. Arch. Endocrinol. Metab. 2022, 66, 748–755.
  2. Holick, M.F.; Binkley, N.C.; Bischoff-Ferrari, H.A.; Gordon, C.M.; Hanley, D.A.; Heaney, R.P.; Murad, M.H.; Weaver, C.M. Evaluation, Treatment, and Prevention of Vitamin D Deficiency: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 2011, 96, 1911–1930.
  3. Graham, L. IOM Releases Report on Dietary Reference Intakes for Calcium and Vitamin D. Am. Fam. Physician 2011, 83, 1352.
  4. Holick, M.F. The Vitamin D Deficiency Pandemic: Approaches for Diagnosis, Treatment and Prevention. Rev. Endocr. Metab. Disord. 2017, 18, 153–165.
  5. Liu, Z.; Huang, S.; Yuan, X.; Wang, Y.; Liu, Y.; Zhou, J. The Role of Vitamin D Deficiency in the Development of Paediatric Diseases. Ann. Med. 2023, 55, 127–135.
  6. Bianchi, S.; Maffei, S.; Prontera, C.; Battaglia, D.; Vassalle, C. Preanalytical, Analytical (DiaSorin LIAISON) and Clinical Variables Potentially Affecting the 25-OH Vitamin D Estimation. Clin. Biochem. 2012, 45, 1652–1657.
  7. Harvey, S.M.; Murphy, V.E.; Gibson, P.G.; Clarke, M.; Jensen, M.E. The Impact of Sample Type on Vitamin d Quantification and Clinical Classification during Pregnancy. Nutrients 2020, 12, 3872.
  8. Yu, C.L.; Falk, R.T.; Kimlin, M.G.; Rajaraman, P.; Sigurdson, A.J.; Horst, R.L.; Cosentino, L.M.; Linet, M.S.; Freedman, D.M. The Impact of Delayed Blood Centrifuging, Choice of Collection Tube, and Type of Assay on 25-Hydroxyvitamin D Concentrations. Cancer Causes Control 2010, 21, 643–648.
  9. Wielders, J.P.M.; Wijnberg, F.A. Preanalytical Stability of 25(OH)-Vitamin D3 in Human Blood or Serum at Room Temperature: Solid as a Rock. Clin. Chem. 2009, 55, 1584–1585.
  10. Battault, S.; Whiting, S.J.; Peltier, S.L.; Sadrin, S.; Gerber, G.; Maixent, J.M. Vitamin D Metabolism, Functions and Needs: From Science to Health Claims. Eur. J. Nutr. 2013, 52, 429–441.
  11. Borai, A.; Khalil, H.; Alghamdi, B.; Alhamdi, R.; Ali, N.; Bahijri, S.; Ferns, G. The Pre-Analytical Stability of 25-Hydroxyvitamin D: Storage and Mixing Effects. J. Clin. Lab. Anal. 2020, 34, e23037.
  12. Colak, A.; Toprak, B.; Dogan, N.; Ustuner, F. Effect of Sample Type, Centrifugation and Storage Conditions on Vitamin D Concentration. Biochem. Med. 2013, 23, 321–325.
  13. Zelzer, S.; Meinitzer, A.; Enko, D.; Simstich, S.; Le Goff, C.; Cavalier, E.; Herrmann, M.; Goessler, W. Simultaneous Determination of 24,25- and 25,26-Dihydroxyvitamin D3 in Serum Samples with Liquid-Chromatography Mass Spectrometry–A Useful Tool for the Assessment of Vitamin D Metabolism. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2020, 1158, 122394.
  14. Cavalier, E. Long-Term Stability of 25-Hydroxyvitamin D: Importance of the Analytical Method and of the Patient Matrix. Clin. Chem. Lab. Med. 2021, 59, E389–E391.
  15. Carter, G.D. 25-Hydroxyvitamin D Assays: The Quest for Accuracy. Clin. Chem. 2009, 55, 1300–1302.
  16. Fraser, W.D.; Milan, A.M. Vitamin D Assays: Past and Present Debates, Difficulties, and Developments. Calcif. Tissue Int. 2013, 92, 118–127.
  17. Tsiaras, W.G.; Weinstock, M.A. Factors Influencing Vitamin d Status. Acta Derm. Venereol. 2011, 91, 115–124.
  18. Kimlin, M.G. Geographic Location and Vitamin D Synthesis. Mol. Asp. Med. 2008, 29, 453–461.
  19. Engelsen, O. The Relationship between Ultraviolet Radiation Exposure and Vitamin D Status. Nutrients 2010, 2, 482–495.
  20. Spiro, A.; Buttriss, J.L. Vitamin D: An Overview of Vitamin D Status and Intake in Europe. Nutr. Bull. 2014, 39, 322–350.
  21. Aldrees, T.; Alohali, S.; Albosaily, A.; Almatrafi, S.; Aldhahri, S. Seasonal Variations in Serum Levels of Vitamin D and Other Biochemical Markers among KSA Patients Prior to Thyroid Surgery. J. Taibah Univ. Med. Sci. 2020, 15, 522–528.
  22. Karagüzel, G.; Dilber, B.; Çan, G.; Ökten, A.; Deǧer, O.; Holick, M.F. Seasonal Vitamin D Status of Healthy Schoolchildren and Predictors of Low Vitamin D Status. J. Pediatr. Gastroenterol. Nutr. 2014, 58, 654–660.
  23. Bjarnadottir, A.; Kristjansdottir, A.G.; Hrafnkelsson, H.; Johannsson, E.; Magnusson, K.T.; Thorsdottir, I. Insufficient Autumn Vitamin D Intake and Low Vitamin D Status in 7-Year-Old Icelandic Children. Public Health Nutr. 2015, 18, 208–217.
  24. Petersen, R.A.; Damsgaard, C.T.; Dalskov, S.M.; Sorensen, L.B.; Hjorth, M.F.; Ritz, C.; Kjolbæk, L.; Andersen, R.; Tetens, I.; Krarup, H.; et al. Vitamin D Status and Its Determinants during Autumn in Children at Northern Latitudes: A Cross-Sectional Analysis from the Optimal Well-Being, Development and Health for Danish Children through a Healthy New Nordic Diet (OPUS) School Meal Study. Br. J. Nutr. 2016, 115, 239–250.
  25. Hansen, L.; Tjønneland, A.; Køster, B.; Brot, C.; Andersen, R.; Cohen, A.S.; Frederiksen, K.; Olsen, A. Vitamin D Status and Seasonal Variation among Danish Children and Adults: A Descriptive Study. Nutrients 2018, 10, 1801.
  26. Pierrot-Deseilligny, C.; Souberbielle, J.C. Is Hypovitaminosis D One of the Environmental Risk Factors for Multiple Sclerosis? Brain 2010, 133, 1869–1888.
  27. Bhattoa, H.P.; Nagy, E.; More, C.; Kappelmayer, J.; Balogh, A.; Kalina, E.; Antal-Szalmas, P. Prevalence and Seasonal Variation of Hypovitaminosis D and Its Relationship to Bone Metabolism in Healthy Hungarian Men over 50 Years of Age: The HunMen Study. Osteoporos. Int. 2013, 24, 179–186.
  28. Cashman, K.D.; Dowling, K.G.; Škrabáková, Z.; Gonzalez-Gross, M.; Valtueña, J.; De Henauw, S.; Moreno, L.; Damsgaard, C.T.; Michaelsen, K.F.; Mølgaard, C.; et al. Vitamin D Deficiency in Europe: Pandemic? Am. J. Clin. Nutr. 2016, 103, 1033–1044.
  29. Ghareghani, M.; Reiter, R.J.; Zibara, K.; Farhadi, N. Latitude, Vitamin D, Melatonin, and Gut Microbiota Act in Concert to Initiate Multiple Sclerosis: A New Mechanistic Pathway. Front. Immunol. 2018, 9, 2484.
  30. Datta, P.; Philipsen, P.A.; Olsen, P.; Petersen, B.; Johansen, P.; Morling, N.; Wulf, H.C. Major Inter-Personal Variation in the Increase and Maximal Level of 25-Hydroxy Vitamin D Induced by UVB. Photochem. Photobiol. Sci. 2016, 15, 536–545.
  31. Vassalle, C.; Pérez-López, F. The Importance of Some Analytical Aspects and Confounding Factors in Relation to Clinical Interpretation of Results. In Vitamin D: Daily Requirements, Dietary Sources and Symptoms of Deficiency; Nova Publisher: New York, NY, USA, 2013; ISBN 978-1-62808-816-8.
  32. Meehan, M.; Penckofer, S. The Role of Vitamin D in the Aging Adult. J. Aging Gerontol. 2014, 2, 60–71.
  33. Kim, C.S.; Kim, S.W. Vitamin D and Chronic Kidney Disease. Korean J. Intern. Med. 2014, 29, 416–427.
  34. Jean, G.; Souberbielle, J.C.; Chazot, C. Vitamin D in Chronic Kidney Disease and Dialysis Patients. Nutrients 2017, 9, 328.
  35. Muscogiuri, G.; Barrea, L.; Di Somma, C.; Laudisio, D.; Salzano, C.; Pugliese, G.; de Alteriis, G.; Colao, A.; Savastano, S. Sex Differences of Vitamin D Status across BMI Classes: An Observational Prospective Cohort Study. Nutrients 2019, 11, 3034.
  36. Heaney, R.P.; Recker, R.R.; Grote, J.; Horst, R.L.; Armas, L.A.G. Vitamin D3 Is More Potent than Vitamin D2in Humans. J. Clin. Endocrinol. Metab. 2011, 96, 447–452.
  37. Nimitphong, H.; Park, E.; Lee, M.J. Vitamin D Regulation of Adipogenesis and Adipose Tissue Functions. Nutr. Res. Pract. 2020, 14, 553–567.
  38. Pereira-Santos, M.; Costa, P.R.F.; Assis, A.M.O.; Santos, C.A.S.T.; Santos, D.B. Obesity and Vitamin D Deficiency: A Systematic Review and Meta-Analysis. Obes. Rev. 2015, 16, 341–349.
  39. Wang, X.; Chang, X.; Zhu, Y.; Wang, H.; Sun, K. Metabolically Obese Individuals of Normal Weight Have a High Risk of 25-Hydroxyvitamin D Deficiency. Am. J. Med. Sci. 2016, 352, 360–367.
  40. Fiamenghi, V.I.; de Mello, E.D. Vitamin D Deficiency in Children and Adolescents with Obesity: A Meta-Analysis. J. Pediatr. 2021, 97, 273–279.
  41. Abbas, M.A. Physiological Functions of Vitamin D in Adipose Tissue. J. Steroid Biochem. Mol. Biol. 2017, 165, 369–381.
  42. Verweij, K.J.; Mosing, M.A.; Zietsch, B.P.; Medlan, M. Estimating Heritability from Twin Studies. Stat. Hum. Genet. Methods Protoc. Methods Mol. Biol. 2012, 850, 151–170.
  43. Karohl, C.; Su, S.; Kumari, M.; Tangpricha, V.; Veledar, E.; Vaccarino, V.; Raggi, P. Heritability and Seasonal Variability of Vitamin D Concentrations in Male Twins. Am. J. Clin. Nutr. 2010, 92, 1393–1398.
  44. Orton, S.M.; Morris, A.P.; Herrera, B.M.; Ramagopalan, S.V.; Lincoln, M.R.; Chao, M.J.; Vieth, R.; Sadovnick, A.D.; Ebers, G.C. Evidence for Genetic Regulation of Vitamin D Status in Twins with Multiple Sclerosis. Am. J. Clin. Nutr. 2008, 88, 441–447.
  45. Yu, H.J.; Kwon, M.J.; Woo, H.Y.; Park, H. Analysis of 25-Hydroxyvitamin D Status According to Age, Gender, and Seasonal Variation. J. Clin. Lab. Anal. 2016, 30, 905–911.
  46. Dastani, Z.; Li, R.; Richards, B. Genetic Regulation of Vitamin D Levels. Calcif. Tissue Int. 2013, 92, 106–117.
  47. Lander, E.; Kruglyak, L. Genetic Dissection of Complex Traits: Guidelines for Interpreting and Reporting Linkage Results. Nat. Genet. 1995, 11, 241–247.
  48. Shinkyo, R.; Sakaki, T.; Kamakura, M.; Ohta, M.; Inouye, K. Metabolism of Vitamin D by Human Microsomal CYP2R1. Biochem. Biophys. Res. Commun. 2004, 324, 451–457.
  49. McGrath, J.J.; Saha, S.; Burne, T.H.J.; Eyles, D.W. A Systematic Review of the Association between Common Single Nucleotide Polymorphisms and 25-Hydroxyvitamin D Concentrations. J. Steroid Biochem. Mol. Biol. 2010, 121, 471–477.
  50. Sakaki, T.; Kagawa, N.; Yamamoto, K.; Inouye, K. Metabolism of Vitamin D3 by Cytochromes P450. Front. Biosci. 2005, 10, 119–134.
  51. Benjamin, E.J.; Dupuis, J.; Larson, M.G.; Lunetta, K.L.; Booth, S.L.; Govindaraju, D.R.; Kathiresan, S.; Keaney, J.F.; Keyes, M.J.; Lin, J.P.; et al. Genome-Wide Association with Select Biomarker Traits in the Framingham Heart Study. BMC Med. Genet. 2007, 8, S11.
  52. Jiang, X.; Kiel, D.P.; Kraft, P. The Genetics of Vitamin D. Bone 2019, 126, 59–77.
  53. Wang, T.T.; Tavera-Mendoza, L.E.; Laperriere, D.; Libby, E.; MacLeod, N.B.; Nagai, Y.; Bourdeau, V.; Konstorum, A.; Lallemant, B.; Zhang, R.; et al. Large-Scale in Silico and Microarray-Based Identification of Direct 1,25-Dihydroxyvitamin D3 Target Genes. Mol. Endocrinol. 2005, 19, 2685–2695.
  54. Bouillon, R.; Marcocci, C.; Carmeliet, G.; Bikle, D.; White, J.H.; Dawson-Hughes, B.; Lips, P.; Munns, C.F.; Lazaretti-Castro, M.; Giustina, A.; et al. Skeletal and Extraskeletal Actions of Vitamin D: Current Evidence and Outstanding Questions. Endocr. Rev. 2019, 40, 1109–1151.
  55. Marino, R.; Misra, M. Extra-Skeletal Effects of Vitamin D. Nutrients 2019, 11, 1460.
  56. Goncalves-Mendes, N.; Talvas, J.; Dualé, C.; Guttmann, A.; Corbin, V.; Marceau, G.; Sapin, V.; Brachet, P.; Evrard, B.; Laurichesse, H.; et al. Impact of Vitamin D Supplementation on Influenza Vaccine Response and Immune Functions in Deficient Elderly Persons: A Randomized Placebo-Controlled Trial. Front. Immunol. 2019, 10, 65.
  57. Zmijewski, M.A. Vitamin D and Human Health. Int. J. Mol. Sci. 2019, 20, 145.
  58. Modarresi-Ghazani, F.; Hejazi, M.E.; Gharekhani, A.; Entezari-Maleki, T. Role of Vitamin D in Cardiovascular Disease. Arch. Iran. Med. 2016, 19, 359–362.
  59. Kim, D.H.; Meza, C.A.; Clarke, H.; Kim, J.S.; Hickner, R.C. Vitamin D and Endothelial Function. Nutrients 2020, 12, 575.
  60. Molinari, C.; Uberti, F.; Grossini, E.; Vacca, G.; Carda, S.; Invernizzi, M.; Cisari, C. 1α,25-Dihydroxycholecalciferol Induces Nitric Oxide Production in Cultured Endothelial Cells. Cell. Physiol. Biochem. 2011, 27, 661–668.
  61. Andrukhova, O.; Slavic, S.; Zeitz, U.; Riesen, S.C.; Heppelmann, M.S.; Ambrisko, T.D.; Markovic, M.; Kuebler, W.M.; Erben, R.G. Vitamin D Is a Regulator of Endothelial Nitric Oxide Synthase and Arterial Stiffness in Mice. Mol. Endocrinol. 2014, 28, 53–64.
  62. Jain, S.K.; Micinski, D.; Huning, L.; Kahlon, G.; Bass, P.F.; Levine, S.N. Vitamin D and L-Cysteine Levels Correlate Positively with GSH and Negatively with Insulin Resistance Levels in the Blood of Type 2 Diabetic Patients. Eur. J. Clin. Nutr. 2014, 68, 1148–1153.
  63. Nakai, K.; Fujii, H.; Kono, K.; Goto, S.; Kitazawa, R.; Kitazawa, S.; Hirata, M.; Shinohara, M.; Fukagawa, M.; Nishi, S. Vitamin D Activates the Nrf2-Keap1 Antioxidant Pathway and Ameliorates Nephropathy in Diabetic Rats. Am. J. Hypertens. 2014, 27, 586–595.
  64. Bhat, M.; Ismail, A. Vitamin D Treatment Protects against and Reverses Oxidative Stress Induced Muscle Proteolysis. J. Steroid Biochem. Mol. Biol. 2015, 152, 171–179.
  65. Calton, E.K.; Keane, K.N.; Newsholme, P.; Soares, M.J. The Impact of Vitamin D Levels on Inflammatory Status: A Systematic Review of Immune Cell Studies. PLoS ONE 2015, 10, e0141770.
  66. Li, Y.C. Molecular Mechanism of Vitamin D in the Cardiovascular System. J. Investig. Med. 2011, 59, 868–871.
  67. Turin, A.; Bax, J.J.; Doukas, D.; Joyce, C.; Lopez, J.J.; Mathew, V.; Pontone, G.; Shah, F.; Singh, S.; Wilber, D.J.; et al. Interactions Among Vitamin D, Atrial Fibrillation, and the Renin-Angiotensin-Aldosterone System. Am. J. Cardiol. 2018, 122, 780–784.
  68. Li, Y.C.; Kong, J.; Wei, M.; Chen, Z.-F.; Liu, S.Q.; Cao, L.-P. 1,25-Dihydroxyvitamin D3 Is a Negative Endocrine Regulator of the Renin-Angiotensin System. J. Clin. Investig. 2002, 110, 229–238.
  69. Yuan, W.; Pan, W.; Kong, J.; Zheng, W.; Szeto, F.L.; Wong, K.E.; Cohen, R.; Klopot, A.; Zhang, Z.; Yan, C.L. 1,25-Dihydroxyvitamin D3 Suppresses Renin Gene Transcription by Blocking the Activity of the Cyclic AMP Response Element in the Renin Gene Promoter. J. Biol. Chem. 2007, 282, 29821–29830.
  70. Zhou, C.; Lu, F.; Cao, K.; Xu, D.; Goltzman, D.; Miao, D. Calcium-Independent and 1,25(OH)2D3-Dependent Regulation of the Renin-Angiotensin System in 1α-Hydroxylase Knockout Mice. Kidney Int. 2008, 74, 170–179.
  71. Zhang, W.; Chen, L.; Zhang, L.; Xiao, M.; Ding, J.; Goltzman, D.; Miao, D. Administration of Exogenous 1,25(OH)2D3 Normalizes Overactivation of the Central Renin-Angiotensin System in 1α(OH)Ase Knockout Mice. Neurosci. Lett. 2015, 588, 184–189.
  72. Tomaschitz, A.; Pilz, S.; Ritz, E.; Grammer, T.; Drechsler, C.; Boehm, B.O.; März, W. Independent Association between 1,25-Dihydroxyvitamin D, 25-Hydroxyvitamin D and the Renin-Angiotensin System. The Ludwigshafen Risk and Cardiovascular Health (LURIC) Study. Clin. Chim. Acta 2010, 411, 1354–1360.
  73. Bernini, G.; Carrara, D.; Bacca, A.; Carli, V.; Virdis, A.; Rugani, I.; Duranti, E.; Ghiadoni, L.; Bernini, M.; Taddei, S. Effect of Acute and Chronic Vitamin D Administration on Systemic Renin Angiotensin Systemin Essential Hypertensives and Controls. J. Endocrinol. Investig. 2013, 36, 216–220.
  74. McMullan, C.J.; Borgi, L.; Curhan, G.C.; Fisher, N.; Forman, J.P. The Effect of Vitamin D on Renin-Angiotensin System Activation and Blood Pressure: A Randomized Control Trial. J. Hypertens. 2016, 35, 822–829.
  75. Kunutsor, S.K.; Apekey, T.A.; Steur, M. Vitamin D and Risk of Future Hypertension: Meta-Analysis of 283,537 Participants. Eur. J. Epidemiol. 2013, 28, 205–221.
  76. Zhang, D.; Cheng, C.; Wang, Y.; Sun, H.; Yu, S.; Xue, Y.; Liu, Y.; Li, W.; Li, X. Effect of Vitamin D on Blood Pressure and Hypertension in the General Population: An Update Meta-Analysis of Cohort Studies and Randomized Controlled Trials. Prev. Chronic Dis. 2020, 17, E03.
  77. Kunutsor, S.K.; Burgess, S.; Munroe, P.B.; Khan, H. Vitamin D and High Blood Pressure: Causal Association or Epiphenomenon? Eur. J. Epidemiol. 2014, 29, 1–14.
  78. Shu, L.; Huang, K. Effect of Vitamin D Supplementation on Blood Pressure Parameters in Patients with Vitamin D Deficiency: A Systematic Review and Meta-Analysis. J. Am. Soc. Hypertens. 2018, 12, 488–496.
  79. Elliott, P.; McKenna, W. Hypertrophic Cardiomyopathy: A 50th Anniversary. Heart 2008, 94, 1247–1248.
  80. Rodríguez, A.J.; Scott, D.; Srikanth, V.; Ebeling, P. Effect of Vitamin D Supplementation on Measures of Arterial Stiffness: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Clin. Endocrinol. 2016, 84, 645–657.
  81. Codoñer-Franch, P.; Tavárez-Alonso, S.; Simó-Jordá, R.; Laporta-Martín, P.; Carratalá-Calvo, A.; Alonso-Iglesias, E. Vitamin D Status Is Linked to Biomarkers of Oxidative Stress, Inflammation, and Endothelial Activation in Obese Children. J. Pediatr. 2012, 161, 848–854.
  82. Gradinaru, D.; Borsa, C.; Ionescu, C.; Margina, D.; Prada, G.I.; Jansen, E. Vitamin D Status and Oxidative Stress Markers in the Elderly with Impaired Fasting Glucose and Type 2 Diabetes Mellitus. Aging Clin. Exp. Res. 2012, 24, 595–602.
  83. Asghari, S.; Hamedi-Shahraki, S.; Amirkhizi, F. Vitamin D Status and Systemic Redox Biomarkers in Adults with Obesity. Clin. Nutr. ESPEN 2021, 45, 292–298.
  84. Cӑtoi, A.F.; Iancu, M.; Pârvu, A.E.; Cecan, A.D.; Bidian, C.; Chera, E.I.; Pop, I.D.; Macri, A.M. Relationship between 25 Hydroxyvitamin d, Overweight/Obesity Status, pro-Inflammatory and Oxidative Stress Markers in Patients with Type 2 Diabetes: A Simplified Empirical Path Model. Nutrients 2021, 13, 2889.
  85. Dhas, Y.; Banerjee, J.; Damle, G.; Mishra, N. Serum 25(OH)D Concentration and Its Association with Inflammation and Oxidative Stress in the Middle-Aged Indian Healthy and Diabetic Subjects. Steroids 2020, 154, 951–957.
  86. Jaksic, M.; Martinovic, M.; Gligorovic-Barhanovic, N.; Vujacic, A.; Djurovic, D.; Nedovic-Vukovic, M. Association between Inflammation, Oxidative Stress, Vitamin D, Copper and Zinc with Pre-Obesity and Obesity in School Children from the City of Podgorica, Montenegro. J. Pediatr. Endocrinol. Metab. 2019, 32, 951–957.
  87. Verdoia, M.; Nardin, M.; Gioscia, R.; Afifeh, A.M.S.; Viglione, F.; Negro, F.; Marcolongo, M.; Luca, G. De Association between Vitamin D Deficiency and Serum Homocysteine Levels and Its Relationship with Coronary Artery Disease. J. Thromb. Thrombolysis 2021, 52, 523–531.
  88. Danikiewicz, A.; Hudzik, B.; Nowak, J.; Kowalska, J.; Zieleń-Zynek, I.; Szkodzinski, J.; Tun, H.N.; Zubelewicz-Szkodzinska, B. Serum Gamma Glutamyltransferase Is Associated with 25-Hydroxyvitamin d Status in Elderly Patients with Stable Coronary Artery Disease. Int. J. Environ. Res. Public Health 2020, 17, 8980.
  89. Machulsky, N.F.; Barchuk, M.; Gagliardi, J.; González, D.; Lombardo, M.; Escudero, A.G.; Gigena, G.; Blanco, F.; Schreier, L.; Fabre, B.; et al. Vitamin D Is Related to Markers of Vulnerable Plaque in Acute Myocardial Infarction. Curr. Vasc. Pharmacol. 2017, 15, 355–360.
  90. Tomson, J.; Emberson, J.; Hill, M.; Gordon, A.; Armitage, J.; Shipley, M.; Collins, R.; Clarke, R. Vitamin D and Risk of Death from Vascular and Non-Vascular Causes in the Whitehall Study and Meta-Analyses of 12 000 Deaths. Eur. Heart J. 2013, 34, 1365–1374.
  91. Gaksch, M.; Jorde, R.; Grimnes, G.; Joakimsen, R.; Schirmer, H.; Wilsgaard, T.; Mathiesen, E.B.; Njølstad, I.; Løchen, M.L.; Maürz, W.; et al. Vitamin D and Mortality: Individual Participant Data Meta-Analysis of Standardized 25-Hydroxyvitamin D in 26916 Individuals from a European Consortium. PLoS ONE 2017, 12, e0170791.
  92. Yang, J.; Ou-Yang, J.; Huang, J.; Wilhelm, M. Low Serum Vitamin D Levels Increase the Mortality of Cardiovascular Disease in Older Adults: A Dose-Response Meta-Analysis of Prospective Studies. Medicine 2019, 98, 810–819.
  93. Zhang, R.; Li, B.; Gao, X.; Tian, R.; Pan, Y.; Jiang, Y.; Gu, H.; Wang, Y.; Wang, Y.; Liu, G. Serum 25-HydroxyVitamin D and the Risk of Cardiovascular Disease: Dose-Response Meta-Analysis of Prospective Studies1-3. Am. J. Clin. Nutr. 2017, 105, 810–819.
  94. Elamin, M.B.; Elnour, N.O.A.; Elamin, K.B.; Fatourechi, M.M.; Alkatib, A.A.; Almandoz, J.P.; Liu, H.; Lane, M.A.; Mullan, R.J.; Hazem, A.; et al. Vitamin D and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis. J. Clin. Endocrinol. Metab. 2011, 96, 1931–1942.
  95. Kalvandi, F.; Azarbayjani, M.A.; Azizbeigi, R.; Azizbeigi, K. Elastic Resistance Training Is More Effective than Vitamin D3 Supplementation in Reducing Oxidative Stress and Strengthen Antioxidant Enzymes in Healthy Men. Eur. J. Clin. Nutr. 2022, 76, 610–615.
  96. Asemi, Z.; Samimi, M.; Tabassi, Z.; Shakeri, H.; Esmaillzadeh, A. Vitamin D Supplementation Affects Serum High-Sensitivity C-Reactive Protein, Insulin Resistance, and Biomarkers of Oxidative Stress in Pregnant Women. J. Nutr. 2013, 143, 1432–1438.
  97. Timar, A.; Saberi-Karimian, M.; Ghazizadeh, H.; Parizadeh, S.M.R.; Sabbaghzadeh, R.; Emadzadeh, M.; Eshaghi, F.; Tavallaie, S.; Ferns, G.A.; Ghayour-Mobarhan, M. Evaluation of the Serum Prooxidant-Antioxidant Balance before and after Vitamin D Supplementation in Adolescent Iranian Girls. Adv. Med. Sci. 2019, 64, 174–180.
  98. de Medeiros Cavalcante, I.G.; Silva, A.S.; Costa, M.J.C.; Persuhn, D.C.; Issa, C.T.M.I.; de Luna Freire, T.L.; da Conceição Rodrigues Gonçalves, M. Effect of Vitamin D3 Supplementation and Influence of BsmI Polymorphism of the VDR Gene of the Inflammatory Profile and Oxidative Stress in Elderly Women with Vitamin D Insufficiency Vitamin D3 Megadose Reduces Inflammatory Markers. Exp. Gerontol. 2015, 66, 10–16.
  99. Scholten, S.; Sergeev, I.; Birger, C.; Song, Q. Effects of Vitamin D and Quercetin, Alone and in Combination, on Cardiorespiratory Fitness and Muscle Function in Physically Active Male Adults. Open Access J. Sport. Med. 2015, 6, 229–239.
  100. Nikooyeh, B.; Neyestani, T.R.; Tayebinejad, N.; Alavi-Majd, H.; Shariatzadeh, N.; Kalayi, A.; Zahedirad, M.; Heravifard, S.; Salekzamani, S. Daily Intake of Vitamin D- or Calcium-Vitamin D-Fortified Persian Yogurt Drink (Doogh) Attenuates Diabetes-Induced Oxidative Stress: Evidence for Antioxidative Properties of Vitamin D. J. Hum. Nutr. Diet. 2014, 27, 276–823.
  101. Tamadon, M.R.; Soleimani, A.; Keneshlou, F.; Mojarrad, M.Z.; Bahmani, F.; Naseri, A.; Kashani, H.H.; Hosseini, E.S.; Asemi, Z. Clinical Trial on the Effects of Vitamin D Supplementation on Metabolic Profiles in Diabetic Hemodialysis. Horm. Metab. Res. 2018, 50, 50–55.
  102. Johny, E.; Jala, A.; Nath, B.; Alam, M.J.; Kuladhipati, I.; Das, R.; Borkar, R.M.; Adela, R. Vitamin D Supplementation Modulates Platelet-Mediated Inflammation in Subjects With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. Front. Immunol. 2022, 13, 869591.
  103. Pasupuleti, P.; Suchitra, M.M.; Bitla, A.R.; Sachan, A. Attenuation of Oxidative Stress, Interleukin-6, High-Sensitivity C-Reactive Protein, Plasminogen Activator Inhibitor-1, and Fibrinogen with Oral Vitamin D Supplementation in Patients with T2DM Having Vitamin D Deficiency. J. Lab. Physicians 2022, 14, 190–196.
  104. Thethi, T.K.; Bajwa, M.A.; Ghanim, H.; Jo, C.; Weir, M.; Goldfine, A.B.; Umpierrez, G.; Desouza, C.; Dandona, P.; Fang-Hollingsworth, Y.; et al. Effect of Paricalcitol on Endothelial Function and Inflammation in Type 2 Diabetes and Chronic Kidney Disease. J. Diabetes Complicat. 2015, 29, 433–437.
  105. Yiu, Y.F.; Yiu, K.H.; Siu, C.W.; Chan, Y.H.; Li, S.W.; Wong, L.Y.; Lee, S.W.L.; Tam, S.; Wong, E.W.K.; Lau, C.P.; et al. Randomized Controlled Trial of Vitamin D Supplement on Endothelial Function in Patients with Type 2 Diabetes. Atherosclerosis 2013, 227, 140–146.
  106. Renke, G.; Starling-Soares, B.; Baesso, T.; Petronio, R.; Aguiar, D.; Paes, R. Effects of Vitamin D on Cardiovascular Risk and Oxidative Stress. Nutrients 2023, 15, 769.
  107. Pei, Y.Y.; Zhang, Y.; Peng, X.C.; Liu, Z.R.; Xu, P.; Fang, F. Association of Vitamin D Supplementation with Cardiovascular Events: A Systematic Review and Meta-Analysis. Nutrients 2022, 14, 3158.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Endocrinology & Metabolism
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Giulia Della Nera
,
Laura Sabatino
,
Melania Gaggini
,
Francesca Gorini
,
Cristina Vassalle
View Times: 214
Revisions: 2 times (View History)
Update Date: 15 Jun 2023
Table of Contents
    1000/1000
    Hot Most Recent
    Feedback